Home » Stocks » IART

Integra LifeSciences Holdings Corporation (IART)

Stock Price: $69.45 USD -0.15 (-0.22%)
Updated Jun 15, 2021 4:00 PM EDT - Market closed
After-hours: $72.30 +2.85 (4.10%) Jun 15, 6:13 PM
Market Cap 5.88B
Revenue (ttm) 1.38B
Net Income (ttm) 170.11M
Shares Out 84.50M
EPS (ttm) 1.99
PE Ratio 34.85
Forward PE 25.13
Dividend n/a
Dividend Yield n/a
Trading Day June 15
Last Price $69.45
Previous Close $69.60
Change ($) -0.15
Change (%) -0.22%
Day's Open 69.86
Day's Range 69.26 - 70.08
Day's Volume 210,164
52-Week Range 42.12 - 77.40

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Integra's (IART) CSS segment too reflects a gradual recovery in procedure-based market as well as an improvement in hospital capital spending during the first quarter.

2 weeks ago - Zacks Investment Research

Integra (IART) reported earnings 30 days ago. What's next for the stock?

2 weeks ago - Zacks Investment Research

PRINCETON, N.J., May 20, 2021 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will host an Investor Day meeting from 8:30 a.m. ...

3 weeks ago - GlobeNewsWire

PRINCETON, N.J., May 07, 2021 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will host an Investor Day meeting from 8:30 a.m. ...

1 month ago - GlobeNewsWire

Integra's (IART) first-quarter revenues improved year over year on organic growth across Codman Specialty Surgical and Tissue Technologies segments.

1 month ago - Zacks Investment Research

Integra (IART) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

1 month ago - Zacks Investment Research

Integra (IART) delivered earnings and revenue surprises of 23.21% and 2.92%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Shares of Integra Lifesciences (NASDAQ:IART) rose 1.5% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share increased 43.75% over the past year to $0.69, whi...

1 month ago - Benzinga

PRINCETON, N.J., April 28, 2021 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, today reported financial results for the first ...

1 month ago - GlobeNewsWire

The sector's Q1 results are likely to reflect solid earnings and revenue growth on strong base business recovery.

Other stocks mentioned: ABT, ALGN, BSX, DGX, HOLX
1 month ago - Zacks Investment Research

The acquisition of ACell, and faster recovery growth rate in Japan and China are likely to have helped recover Integra's first-quarter 2021 performance.

1 month ago - Zacks Investment Research

Here are five orthopedic device stocks, Integra (IART), Conformis (CFMS), SeaSpine (SPNE), Zimmer Biomet (ZBH), Orthofix (OFIX), which are expected to continue their run over the next few months.

Other stocks mentioned: CFMS, NUVA, OFIX, SPNE, ZBH
1 month ago - Zacks Investment Research

Integra (IART) is optimistic about maintaining its strength in its international business, along with its portfolio optimization strategy.

1 month ago - Zacks Investment Research

PRINCETON, N.J., April 19, 2021 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART), a leading global medical technology company and manufacturer of SurgiMend Collagen Matrix, to...

1 month ago - GlobeNewsWire

PRINCETON, N.J., April 08, 2021 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will release first quarter 2021 financial resul...

2 months ago - GlobeNewsWire

PRINCETON, N.J., April 01, 2021 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART), a leading global medical technology company, today announced the appointment of Shaundra Clay...

2 months ago - GlobeNewsWire

Investors are optimistic about Integra LifeSciences (IART) stock, owing to its strong international business growth and focus on portfolio optimization.

2 months ago - Zacks Investment Research

Integra LifeSciences (IART) is confident of achieving long-term goals of 5% to 7% revenue growth organically,

2 months ago - Zacks Investment Research

Integra (IART) reported earnings 30 days ago. What's next for the stock?

2 months ago - Zacks Investment Research

Most of Integra's (IART) franchises or products succeed in sustaining the momentum after returning to growth in the third quarter.

3 months ago - Zacks Investment Research

After the rise of 10-year yields terrified investors, the indices “reverse rotated” back into the Nasdaq and out of the Dow. Make the most of this market with today's top buys, from Q.ai's Artificial In...

Other stocks mentioned: ATVI, LLY, NTGR, SWM
3 months ago - Forbes

Integra LifeSciences (IART) is confident of achieving long-term goals of 5% to 7% revenue growth organically.

3 months ago - Zacks Investment Research

Integra (IART) fourth-quarter 2020 revenues fell 1.6% year over year to $388.6 million but rose 5% sequentially.

3 months ago - Zacks Investment Research

PRINCETON, N.J., Feb. 19, 2021 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, announced today that it is participating in the ...

3 months ago - GlobeNewsWire

Integra (IART) delivered earnings and revenue surprises of 13.51% and 0.29%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

Shares of Integra Lifesciences (NASDAQ:IART) moved higher by 0.0% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share increased 23.53% year over year to $0....

3 months ago - Benzinga

Integra Lifesciences Holdings Corp (NASDAQ: IART) reported Q4 adjusted EPS $0.84 better than the consensus estimate of $0.73 and revenues of $388.6 million in line with expectations. Revenues declined 1...

3 months ago - Benzinga

PRINCETON, N.J., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART) today reported financial results for the fourth quarter and full-year ended December 31, 2020,...

3 months ago - GlobeNewsWire

The acquisition is expected to remain accretive to Integra's (IART) revenue growth and adjusted gross margins.

4 months ago - Zacks Investment Research

PRINCETON, N.J., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today announced it completed the previously-discl...

4 months ago - GlobeNewsWire

Integra's (IART) sales improvement in the fourth quarter is likely to have been boosted by on-going business recovery.

5 months ago - Zacks Investment Research

PRINCETON, N.J., Jan. 14, 2021 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, announced today certain unaudited preliminary fo...

5 months ago - GlobeNewsWire

Integra (IART) does not expect the selloff to have a material impact on its 2020 results.

5 months ago - Zacks Investment Research

PRINCETON, N.J., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today announced it has completed its previously a...

5 months ago - GlobeNewsWire

Integra (IART) is optimistic about maintaining a robust product portfolio amid the pandemic-led business disruptions.

5 months ago - Zacks Investment Research

Integra (IART) expects to close the ACell acquisition in the first quarter of 2021, subject to fulfilment of closing conditions.

5 months ago - Zacks Investment Research

PRINCETON, N.J., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, announced today that Peter Arduini, president an...

5 months ago - GlobeNewsWire

Integra LifeSciences is in the late stages of a transition period, rounded off by the recent divestiture of the orthopaedics segment, to be closed next year. The company has had a strong sequential quar...

6 months ago - Seeking Alpha

Let's see if Integra LifeSciences (IART) stock is a good choice for value-oriented investors right now from multiple angles.

6 months ago - Zacks Investment Research

Integra (IART) reported earnings 30 days ago. What's next for the stock?

6 months ago - Zacks Investment Research

Integra's (IART) third-quarter 2020 results reflect mixed segmental performance with strong recovery trends due to coronavirus-led business disruptions.

7 months ago - Zacks Investment Research

Integra LifeSciences Holdings Corporation (IART) CEO Peter Arduini on Q3 2020 Results - Earnings Call Transcript

7 months ago - Seeking Alpha

Integra (IART) delivered earnings and revenue surprises of 40.35% and 0.36%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

7 months ago - Zacks Investment Research

Shares of Integra Lifesciences (NASDAQ:IART) remained unaffected after the company reported Q3 results. Quarterly Results Earnings per share were up 17.65% year over year to $0.80, which beat the estima...

7 months ago - Benzinga

PRINCETON, N.J., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, today reported financial results for the third q...

7 months ago - GlobeNewsWire

Integra (IART) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

7 months ago - Zacks Investment Research

IART vs. ABMD: Which Stock Is the Better Value Option?

Other stocks mentioned: ABMD
8 months ago - Zacks Investment Research

Integra's (IART) sales improvement in the third quarter is broad-based across the major franchises as per preliminary statement.

8 months ago - Zacks Investment Research

PRINCETON, N.J., Oct. 06, 2020 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, announced today certain unaudited preliminary th...

8 months ago - GlobeNewsWire

Smith & Nephew SNN, +2.16% SN, -0.91% said it's buying the extremity orthopedics unit of Integra LifeSciences IART, -0.40% ...

Other stocks mentioned: SNN
8 months ago - Market Watch

About IART

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. It operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, hydrocephalus management systems, intracranial monitoring equipment, and cranial... [Read more...]

Industry
Medical Devices
IPO Date
Aug 16, 1995
CEO
Peter Arduini
Employees
3,700
Stock Exchange
NASDAQ
Ticker Symbol
IART
Full Company Profile

Financial Performance

In 2020, IART's revenue was $1.37 billion, a decrease of -9.60% compared to the previous year's $1.52 billion. Earnings were $133.89 million, an increase of 166.71%.

Financial Statements

Analyst Forecasts

According to 14 analysts, the average rating for IART stock is "Buy." The 12-month stock price forecast is 77.55, which is an increase of 11.66% from the latest price.

Price Target
$77.55
(11.66% upside)
Analyst Consensus: Buy